Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate

Trial Profile

Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LUTHREE
  • Most Recent Events

    • 08 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top